首页> 外文期刊>Journal of cataract and refractive surgery >Preventing intraocular pressure increase after phacoemulsification and the role of perioperative apraclonidine.
【24h】

Preventing intraocular pressure increase after phacoemulsification and the role of perioperative apraclonidine.

机译:预防白内障超声乳化术后眼压升高的作用及围手术期阿克拉可定的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

To evaluate the effectiveness of prophylactic topical apraclonidine 1% in preventing an intraocular pressure (IOP) rise in the early period after uneventful phacoemulsification with intraocular lens (IOL) implantation.District general hospital, United Kingdom.In this prospective masked randomized trial, 61 patients had elective, routine, corneal tunnel, sutureless phacoemulsification with in-the-bag foldable IOL implantation. A single surgeon operated on all the patients. Patients were randomized to receive topical apraclonidine 1% eyedrops (n = 31) or artificial tears (control group, n = 30) 1 hour preoperatively and at the end of the surgery. An observer masked to the perioperative drops used measured the IOP preoperatively and 3 to 6 hours and 16 to 24 hours postoperatively. The primary outcome was the change in IOP between the baseline and the 2 postoperative intervals. The IOP changes within and between the groups were analyzed using the t test and chi-square test.The changes between the postoperative and preoperative IOPs in the study groups were statistically significant (apraclonidine, P = 0.018 and P = 0.007, respectively; artificial tears, P = 0.028 and P = 0.023, respectively; paired t test). There was no significant difference in the postoperative IOP between the apraclonidine and control groups 3 to 6 hours and 16 to 24 hours postoperatively (P = 0.717 and P = 0.497, respectively; independent t test). The mean difference was 0.2 mm Hg (95% confidence interval [CI], -3.4 to 3.1) in the apraclonidine group and 2.2 mm Hg (95% CI, -2.5 to 7.0) in the control group. In each group, a few patients had an IOP greater than 30 mm Hg in the first 24 hours.Prophylactic topical perioperative apraclonidine 1% did not cause a significant reduction in the postoperative IOP when compared with a control group.
机译:为了评估预防性局部应用阿克拉克隆定1%预防在人工晶状体(IOL)植入后的无节状超声乳化术早期早期眼内压(IOP)升高的有效性,该地区英国总医院在这项前瞻性,随机,蒙面随机试验中,有61位患者选择性,常规,角膜隧道,袋内可折叠人工晶状体植入术进行无缝合超声乳化术。一名外科医生对所有患者进行手术。患者被随机分配在术前和手术结束后1小时接受局部1%阿克拉克隆定滴眼液(n = 31)或人工泪液(对照组,n = 30)。观察者对所使用的围手术期滴剂进行掩盖,观察者在术前,术后3至6小时和术后16至24小时测量眼压。主要结果是基线与术后2个间隔之间的眼压变化。用t检验和卡方检验分析各组之间和各组之间的IOP变化。研究组的术后和术前IOP之间的变化具有统计学意义(阿克拉克隆定,P = 0.018和P = 0.007;人工泪液,分别为P = 0.028和P = 0.023;配对t检验)。在术后3至6小时和16至24小时,阿普拉可尼定与对照组的术后IOP没有显着差异(分别为P = 0.717和P = 0.497;独立t检验)。阿普拉可尼定组的平均差异为0.2 mm Hg(95%置信区间[CI],-3.4至3.1),对照组为2.2 mm Hg(95%CI,-2.5至7.0)。在每组中,有少数患者在开始的24小时内眼压大于30毫米汞柱。与对照组相比,术中局部围手术期预防性应用阿普拉可尼定1%不会导致术后眼压显着降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号